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Background: Patients with heart failure and preserved ejection fraction (HFpEF) have a 
poor prognosis, and no therapies have been proven to improve outcomes. It has been 
proposed that heart failure, including HFpEF, represents overlapping syndromes that may 
have different prognoses. We present an exploratory study of patients enrolled in the 
Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) using 
latent class analysis (LCA) with validation using the Candesartan in Heart failure: 
Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved study to 
identify HFpEF subgroups. 
Methods and results: In total, 4113 HFpEF patients randomized to irbesartan or placebo 
were characterized according to 11 clinical features. HFpEF subgroups were identified 
using LCA. Event-free survival and effect of irbesartan on the composite of all-cause 
mortality and cardiovascular hospitalization were determined for each subgroup. 
Subgroup definitions were applied to 3203 patients enrolled in CHARM-Preserved to 
validate observations regarding prognosis and treatment response. Six subgroups were 
identified with significant differences in event-free survival (p<0.001). Clinical profiles 
and prognoses of the 6 subgroups were similar in CHARM-Preserved. The two subgroups 
with the worst event-free survival in both studies were characterized by a high prevalence 
of obesity, hyperlipidemia, diabetes mellitus, anemia, and renal insufficiency (Subgroup 
C) and by female predominance, advanced age, lower body mass index, and high rates of 
atrial fibrillation, valvular disease, renal insufficiency, and anemia (Subgroup F).  
Conclusion: Using a data-driven approach, we identified HFpEF subgroups with 
significantly different prognoses. Further development of this approach for characterizing 
HFpEF subgroups is warranted. 
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Introduction 
Approximately half of heart failure patients have a preserved left ventricular 
ejection fraction (HFpEF). HFpEF patients have a poor prognosis and are more likely to 
be older, female, hypertensive, anemic, and to have atrial fibrillation (AF) than heart 
failure patients with reduced ejection fraction (HFrEF).
1
 Despite multiple clinical trials, no 
therapy has been found to improve HFpEF outcomes. The largest HFpEF trial was the 
Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) in 
which irbesartan therapy failed to affect the composite of death or hospitalization for a 
cardiovascular cause.
2
 Similarly, the Candesartan in Heart failure: Assessment of 
Reduction in Mortality and morbidity (CHARM)-Preserved study showed no reduction in 
the composite of cardiovascular death or HF hospitalization associated with candesartan 
therapy.
3
 Subsequent I-PRESERVE analyses have identified predictors of adverse 
outcomes including age, body mass index (BMI), NT-proBNP, diabetes mellitus (DM), 
coronary artery disease (CAD), and renal insufficiency, but only low NT-proBNP has 
been associated with response to irbesartan.
4-6
  
It has been suggested that both HFrEF and HFpEF patients are comprised of 
overlapping subgroups with respect to etiology, prognosis and likelihood of treatment 
response; that characteristics of some HFpEF subgroups may be different than HFrEF; and 
that some subgroups may be more likely to respond to specific therapies.
7
 Although 
HFpEF patients generally more comorbidities than HFrEF,
8
 HFpEF may not be simply the 
sum of comorbidities. Instead multisystem processes may act synergistically to cause 
clinical HFpEF. One hypothesis proposes that in some patients, HFpEF-associated 
comorbidities produce inflammation that affects endothelial function thereby contributing 
to progression of HFpEF.
9,10
 Furthermore, patients with DM and HFpEF may have 
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increased inflammation, vasoconstriction and worse outcomes including functional 
capacity.
11
 HFpEF trials with vasoprotective agents (renin-angiotensin system 
blockade),
2,3,12
 and anti-inflammatory agents (statins)
13
 have been negative suggesting that 
optimal therapeutic targets have not been identified or optimal targets may be different 
optimal in different HFpEF subgroups. 
Latent class analysis (LCA) identifies groups of individuals with similar clinical 
profiles and has been used for identification, characterization, and validation of disease 
subtypes in several domains including HF.
14,15
 Unlike many clustering methods that 
require continuous variables, LCA is optimized for analysis of categorical variables that 
are frequently encountered in clinical practice such as gender and presence of 
comorbidities. LCA assumes the existence of subgroups or ‘latent classes’ within a 
population that explain patterns of association between clinical features and identifies 
subgroups according to prevalent patterns of those features. When a population has a 
shared disease like HFpEF, latent classes may represent disease subgroups identifiable by 
combinations of several traits rather than a single trait. LCA has been used to develop 
diagnostic criteria for complex diseases and to identify subgroups of diseases including 
HFrEF for risk stratification and determining likelihood of treatment response.
15-17
  
In this retrospective, exploratory analysis, LCA was applied to clinical profiles of 
patients enrolled in I-PRESERVE to identify prevalent HFpEF subgroups and differences 
in outcomes. We hypothesized HFpEF subgroups identified using LCA would vary in 
prognosis and response to irbesartan. We performed a limited validation of these 
observations by applying the same subgroup definitions to HFpEF patients enrolled in 
CHARM-Preserved. We propose that these subgroups provide a starting point for in-depth 
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characterization of HFpEF patients using LCA, most notably with the addition of cardiac 
structure, hemodynamics, and biomarkers.  
 
Methods 
I-PRESERVE trial design 
The design of I-PRESERVE has been described previously.
2
 The study was 
conducted according to the Declaration of Helsinki and approved by ethics committees at 
each center. All patients provided written informed consent. I-PRESERVE enrolled 
HFpEF (EF>45%) patients ≥60 years old with NYHA class II-IV symptoms and HF 
hospitalization within the previous 6 months or NYHA class III-IV symptoms and 
pulmonary congestion by radiograph, left ventricular hypertrophy, left bundle branch 
block, or left atrial enlargement. Patients were double-blind randomized to irbesartan or 
placebo. The primary outcome was all-cause mortality or hospitalization for a 
cardiovascular reason. The secondary outcome was HF hospitalization or death due to 
either HF or sudden death. Mean follow-up was 49.5 months with an annual mortality of 
5.2%, and irbesartan had no effect on the primary endpoint (p=0.35). In total, 4113 
randomized patients had sufficient historical data to be included in LCA.  
 
Subgroup identification 
 Patients were characterized according to 11 prospectively selected clinical 
features: age, gender, BMI, AF, CAD, DM, hyperlipidemia, valvular disease, alcohol use, 
estimated glomerular filtration rate (eGFR), and hematocrit. 
8,18
 Age, gender, BMI, AF, 
CAD, DM, anemia, and eGFR have been studied previously for predicting outcomes and 
treatment response to irbesartan in I-PRESERVE.
2,4-6
 Alcohol use was chosen due to the 
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role of angiotensin II receptor 1 in alcoholic cardiomyopathy.
19
 Valvular disease is an 
independent risk factor for HFpEF
20
 and has possible implications for response to renin-
angiotensin system blockade.
21
 BMI was categorized according to World Health 
Organization Classifications of underweight, normal weight, overweight, and obese. eGFR 
was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation, 
and eGFR was categorized using standard definitions for chronic kidney disease stages 1-
5.
22,23
 Patients were classified as having CAD if they had a history of myocardial 
infarction, angina, or coronary revascularization. Hypertension (88-89%) and race (93-
94% white) were excluded from LCA because their homogeneity suggested they were 
unlikely to discriminate subpopulations of patients. NT-proBNP was excluded because it 
has been identified as a marker of progression of HFpEF and hemodynamic status rather 
than a comorbid condition. A separate LCA combining NT-proBNP with cardiac function, 
hemodynamics, and markers of congestion will be reported separately. All interpretation 
criteria were encoded and applied to primary data using MySQL Server (version 5.5.24, 
Oracle Corporation, Redwood Shores, CA).  
 LCA was performed using the poLCA library in the R statistical package (version 
2.15.0, R Foundation for Statistical Computing, Vienna, Austria).
24
 Latent class 
definitions were derived using maximum-likelihood estimation to identify the most 
common patterns of the 11 variables for a range of 2-10 subgroups. The optimal number 
of subgroups for I-PRESERVE was determined using the first minima of the Bayesian 
Information Criterion (BIC) and 2 statistic. Probabilities of membership in each subgroup 
for every LCA variable were used to determine the most likely subgroup for each patient. 
Derivation of the latent class model and Bayesian determination of an individual patient’s 
subgroup is detailed in the Appendix. In this exploratory study we report the results of the 
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primary 11 variables only. Future work will explore strategies for iterative selection of 
variables to optimize LCA subgroups. 
 
Association between HFpEF subgroup and outcomes 
 Outcomes were analyzed according to the intention-to-treat principle using 
Kaplan-Meier estimates and Cox proportional-hazards models to calculate hazard ratios 
(HR), confidence intervals (CI), and p-values using the stcox function in Stata (StataCorp, 
College Station, TX). Subgroup was treated as a categorical covariate, and interactions 
between irbesartan and outcomes were evaluated in each subgroup. Cox regression was 
repeated with respect to the primary outcome for all categorical LCA components with 
irbesartan as an interaction term using the Bonferroni correction (11 tests) to identify 
individual predictors of prognosis and response to irbesartan. Step-forward multivariate 
analysis was performed using a corrected p-value threshold <0.05. Comprehensive 
multivariate analysis was repeated using all 11 LCA component variables with the 
addition of SBP, LVEF, NT-proBNP, and probability of membership in each of the 
subgroups for each patient as continuous covariates. The likelihood ratio test (LR) and 
Gonen and Heller’s K statistic of concordance were used to determine whether probability 
of subgroup membership added prognostic information to the multivariate models. The K 
statistic was used because it is not sensitive to the degree and patterning of censoring. P-
values from the LR tests and K statistics were averaged over 20 multiply-imputed data 
sets
25
 because a complete case analysis would have excluded 18% of patients in I-
PRESERVE. 
 
External validation (CHARM-Preserved) 
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The design of CHARM-Preserved has been described elsewhere.
3
 CHARM-
Preserved was conducted according to the Declaration of Helsinki, approved by ethics 
committees at each center, and all patients provided written informed consent. CHARM-
Preserved double-blind randomized adults with an EF >40%, NYHA class II-IV 
symptoms for ≥4 weeks and a history of HF hospitalization to candesartan or placebo. The 
primary endpoint was a composite of cardiovascular death or HF hospitalization. Mean 
follow-up was 36.6 months and candesartan had no effect on the primary endpoint 
(p=0.12). For validation, I-PRESERVE primary and secondary outcomes for all subjects 
were derived from primary CHARM-Preserved data. 
HFpEF subgroup definitions derived from I-PRESERVE were applied to all 3203 
CHARM-Preserved patients (Appendix). Only 1986 (62.0%) of CHARM-Preserved 
subjects had hematocrit and serum creatinine levels checked. Laboratory values were not 
imputed for LCA subgroup classification because of the variability in these lab values 
between subgroups in I-PRESERVE and because LCA makes no assumptions about 
distributions of missing data. NT-proBNP was not measured systematically in CHARM-
Preserved. Associations between subgroup, outcome, and interaction with treatment group 
were analyzed using Kaplan-Meier estimates and Cox proportional hazards models as in I-
PRESERVE. Multivariate analyses, LR test, and K statistics were repeated using 20 
multiply-imputed data sets, because 67% of patients in CHARM-Preserved were missing 
at least one value.  
 
Results 
 The optimal number of HFpEF LCA subgroups in I-PRESERVE was 6. 
Distributions of the 11 LCA variables and distributions of baseline LVEF, SBP, and NT-
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proBNP according to subgroup in I-PRESERVE and CHARM-Preserved are summarized 
in Table 1a and 1b, respectively. Coefficients required to calculate the most likely 
subgroup for HFpEF patients are found in Appendix Table C.  
 
Subgroup characteristics 
 Subgroup A (median age 65 years) was 100% men and Subgroup B (median 65 
years) was 96% women. Subgroups A and B had low rates of AF, renal dysfunction, and 
valvular disease, although Subgroup A had more alcohol use and Subgroup B had more 
anemia. Subgroup C (median 70 years) had high rates of obesity, DM, hyperlipidemia, 
CAD, and anemia with worse renal function than other subgroups. Subgroup D (median 
73 years) was 100% women with average rates of DM, hyperlipidemia, and obesity and 
renal insufficiency. Subgroup E (median 75 years) was 100% men with lower BMI, excess 
AF, and CAD. Subgroup F was predominantly women (77.5%) of advanced age (median 
82 years) with lower BMI and high rates of AF, valvular disease, renal dysfunction, and 
anemia. Median baseline LVEF and SBP were similar between all subgroups, although 
median baseline NT-proBNP ranged from 143 (Subgroup B) to 950 pg/mL (Subgroup F). 
Relative subgroup profiles were similar between I-PRESERVE and CHARM-
Preserved, but the distribution of HFpEF subgroups was different due to differences in 
overall patient characteristics between the two trials. CHARM-Preserved included 
younger patients (28.3% < age 60, vs. 100% > age 60), fewer women (40.1% vs. 60.4%, 
p<0.001), and more CAD (65.7%vs. 43.8%, p<0.001). AF (15.8% vs. 29.8%, p<0.001) 
and alcohol use (3.7 vs. 10.8%, p<0.001) were reported less frequently in CHARM-
Preserved, whereas valvular disease was reported more frequently (20.1% vs.10.7%, 
p<0.001). The rate of missing laboratory values was different between subgroups in 
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CHARM-Preserved, ranging from ~35% (Subgroup C) to ~75% (Subgroup A). Where 
available BMI, eGFR, and hematocrit were all significantly lower in CHARM-Preserved 
than I-PRESERVE (p<0.001 for all). 
 
Outcomes 
 The primary and secondary outcomes occurred in 1501 (36.5%) and 871 (21.2%) 
of I-PRESERVE subjects and in in 1220 (40.4%) and 525 (17.4%) CHARM-Preserved 
patients, respectively. There were significant differences in outcomes between subgroups 
in both trials (Figures 1 and 2). Probability of the primary and secondary outcomes for 
each study at 3 years according to treatment group are shown in Tables 2a and 2b. 
Subgroups C and F had the highest rate of both outcomes in both studies whereas 
Subgroup B had the lowest. Irbesartan was not associated with a reduction in either 
outcome overall, but irbesartan was associated with a nominally significant reduction in 
the primary outcome in Subgroup C (HR 0.72, 95% CI 0.53-0.99, p=0.046). No treatment 
effects were observed with respect to the secondary outcome in any subgroup, although 
there were 50% fewer events compared to the primary outcome. There were no significant 
differences in the outcomes between candesartan and placebo arms in any subgroup in 
CHARM-Prserved. 
 
Multivariate analysis 
Of the 11 LCA categorical variables, 7 (age, gender, AF, CAD, DM, 
hyperlipidemia, eGFR) were significantly associated with the primary outcome in 
multivariate analysis corrected for multiple comparisons. No component variables were 
associated with a treatment effect. Subgroup remained significantly associated with the 
 12 
primary outcome when added to categorical multivariate predictors (LR p=0.001), and  
differences in HRs between subgroups were attenuated but similar to those when 
considering subgroup alone. When added to the full multivariate model including all 11 
component variables plus NT-proBNP, SBP, and LVEF (Table 3a), probability of 
membership in each subgroup remained significantly associated with the primary outcome 
(LR p<0.001), and the K statistic increased (0.660 to 0.670). HRs for multivariate 
predictors of the primary outcome in I-PRESERVE were similar in CHARM-Preserved, 
and all were significant with the exception of CAD (p=0.22). Subgroup remained 
significantly associated with the primary outcome when added to categorical multivariate 
predictors (excluding eGFR) in all CHARM-Preserved patients (LR p=0.002), although it 
was not significant when restricted to only patients ≥ age 60 (N=2166, LR p=0.12). When 
combined with the full multivariate model in all CHARM-Preserved patients including 
SBP and LVEF (Table 3b), subgroup was no longer significantly associated with the 
primary outcome (LR p=0.31). As expected, the K (0.628) statistics for the full 
multivariate model were also lower in CHARM-Preserved than in I-PRESERVE, and the 
addition of subgroup had a slight effect K statistics (0.629). When restricted to patients 
age ≥60 (Table 3c), the LR for adding subgroup to the full multivariate model was 0.27 
and the K statistic improved from 0.620 to 0.622, although probability of Subgroup C 
membership remained a significant predictor of the primary outcome (p=0.03). 
As described previously,
6
 in I-PRESERVE NT-proBNP below the median (339 
pg/mL) was associated with favorable response to irbesartan overall (HR 0.74, 95% CI 
0.60-0.90, p=0.003), and NT-proBNP above the median was associated with increased 
risk of the primary outcome (HR 2.14, 95% CI 1.90-2.42, p<0.001). Subgroup C patients 
with low NT-proBNP had a greater reduction in the primary outcome with irbesartan than 
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others (HR 0.45, 95% CI 0.21-0.95, p=0.037), although all other patients with a low NT-
proBNP also showed a treatment effect (HR 0.76, 95% CI 0.62-0.94, p=0.013). Patients 
with high NT-proBNP had no evidence of treatment effect irrespective of subgroup. NT-
proBNP associations could not be validated in CHARM-Preserved. 
 
Discussion 
 Our study demonstrates that multiple specific phenotypes of HFpEF can be 
identified using simple and widely available clinical variables and that these phenotypes 
have significantly different outcome rates. With 7316 patients, this is the largest study of 
cluster-based phenotyping in HFpEF to date. Unlike prior studies that primarily used 
continuous variables,
26
 ours is also the first HFpEF phenotype analysis to use categorical 
variables commonly available in clinical practice. HFpEF likely represents a spectrum of 
overlapping syndromes in which biologic traits and comorbidities intersect in varied 
combinations so that no single trait is unique to any given syndrome.
7
 It is therefore 
plausible that several factors in combination may identify syndromes with implications for 
prognosis as previously suggested in HFrEF patients.
17,27
 Known syndromes may be 
studied but must be prespecified, as it is impossible to calculate HRs for all combinations 
of clinical variables. Furthermore, the huge number of interactions makes it difficult for 
even the most astute clinician to identify similarly complex clinical patterns during routine 
patient care. The strategy presented here uses a data-driven approach to identify prevalent 
constellations of clinical characteristics and focus study on relevant subgroups using 
realistic sample sizes.
16
 As expected there is considerable overlap of individual clinical 
features between subgroups, but our results suggest LCA may be a useful exploratory tool 
for identifying HFpEF sub-populations with higher rates of adverse events or response to a 
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specific intervention and may serve as a starting point for targeted investigation of 
interactions between HFpEF and comorbid conditions. Incorporating additional clinical, 
biomarker, and echocardiographic data will likely refine these phenotype definitions. 
 
Differential prognosis between subgroups 
 Subgroup C had a higher rate of adverse outcomes in the setting of high rates of 
DM and renal dysfunction. These conditions along with the high rates of obesity and 
anemia that also characterize Subgroup C can induce chronic systemic inflammation, and 
it has been postulated that this inflammation may drive both endothelial dysfunction and 
cardiac hypertrophy, resulting in worsening of HFpEF.
9
 A subgroup of HFpEF patients 
enrolled in the RELAX trial was recently identified who were younger and more obese 
with a higher prevalence of renal disease, hypertension, peripheral vascular disease and 
pulmonary disease than other patients.
11
 This subgroup had worse exercise capacity and a 
higher incidence of hospitalization for cardiac or renal causes at one year, although a 
mortality difference was not found likely due to the small sample size (216). In the present 
analysis Subgroup C may represent a more comprehensive description of this phenotype, 
which had an excess of hospitalization and mortality in both I-PRESERVE and CHARM-
Preserved as might be expected based on the outcomes of the diabetic subgroup in 
RELAX.
11
 
Subgroup remained a significant predictor of the primary outcome in I-
PRESERVE when included in multivariate analysis with both the categorical LCA 
variables and with the addition of SBP, LVEF, and NT-proBNP in I-PRESERVE by LR 
with a modest impact on the K statistic. This is somewhat expected, as it has been shown 
previously that when added to several significant predictors, a novel risk factor must have 
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a relatively large effect size (odds ratio ~3) in order to appreciably affect a c-statistic.
28
 
The significance of adding subgroup to clinical variables was less in CHARM-Preserved, 
and the predictive models performed slightly less well. Although the addition of subgroup 
to categorical multivariate predictors of the primary outcome in all patients, it did not 
remain significant when added to multivariate predictors including LVEF and SBP.  
Subgroup C showed evidence of possible benefit from irbesartan with a nominally 
significant reduction in the primary outcome (HR 0.72, p=0.046). A treatment effect in 
Subgroup C was not observed with candesartan in CHARM-Preserved. This could 
represent false discovery, but other factors might also be considered. CHARM-Preserved 
was underpowered to detect a treatment effect in Subgroup C (61% power to detect a 25% 
reduction in event rate at p<0.05). Although Subgroup C was underpowered in both trials, 
the presence of an association in an underpowered sample is suggestive of a significant 
finding, whereas the absence of effect in an underpowered sample is inconclusive. 
Relative differences between clinical profiles of LCA subgroups were similar between the 
studies, but absolute rates of some conditions were different between trials in each 
subgroup possibly affecting potential for treatment response. Finally, previous 
comparative studies have shown differences between angiotensin receptor blockers with 
respect to treating hypertension, proteinuria, and preventing progression of diabetic 
nephropathy.
29-31
 Consequently, prospective evaluation is preferable to validate the role of 
irbesartan in treatment of Subgroup C HFpEF patients. 
 
Use in clinical practice and for clinical trial design 
Probabilities of subgroup membership for each clinical variable can be used to 
classify any HFpEF patient according to the subgroups presented here (Appendix). We 
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include in Online Supplemental Material a spreadsheet tool that calculates the likelihood 
of membership in each HFpEF subgroup based on the 11 LCA component variables using 
the Bayesian approach. Alternatively, it is common to develop simplified criteria from 
latent class definitions by employing methods such as classification trees. Translating 
latent class definitions to simplified criteria for clinical use will be the subject of future 
work.   
 
Limitations 
 This is a retrospective analysis, and all findings must be validated prospectively. 
Because LCA provides a quantitative method for determining an individual’s subgroup 
these subgroup definitions can be applied directly to other HFpEF patients. However the 
coefficients derived in this analysis assume the population of interest is similar to I-
PRESERVE. As shown in the CHARM-Preserved analysis, profiles of subgroups created 
in independent populations using the these coefficients may differ from those in I-
PRESERVE. Validation of multivariate analysis and model performance in CHARM-
Preserved may have been affected by non-random missing laboratory data. Although 
missing laboratory values were imputed, it is possible that imputation was not accurate on 
a subgroup-by-subgroup basis. Subgroups identified by LCA represent statistical 
associations of variables and may not necessarily reflect pathophysiology. Consequently, 
our findings are hypothesis-generating. The present analysis does not reflect an exhaustive 
iterative process of refining the latent class model in part because there are few standards 
for comparing LCA models with different numbers of variables. A systematic approach to 
selecting LCA variables will be the subject of future work to increase the relevance and 
validity of subgroups identified by LCA. 
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Conclusion 
 Using LCA applied to common clinical features, we identified 6 subgroups of 
HFpEF patients with significant differences in event-free survival. Refinement of these 
methods for identifying HFpEF subgroups, expansion of the included variables, and 
validation of our observations prospectively is warranted. 
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Figure 1 – Primary outcome event-free survival according to subgroup, I-
PRESERVE and CHARM-Preserved 
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Figure 2 – Composite heart failure outcome event-free survival according to 
subgroup, I-PRESERVE and CHARM-Preserved 
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Table 1a – Distributions of latent class analysis variables according to HFpEF 
subgroup, I-PRESERVE, N (%) 
 
Subgroup 
 
 
A B C D E F All  
Variables 601 (15) 701 (17) 322 (8) 1248 (30) 760 (18) 481 (12) 4113 
Age, years 
 
      
60-70 562 (94) 645 (92) 143 (44) 278 (22) 89 (12) 21 (4) 1738 (42) 
70-80 0 (0) 22 (3) 152 (47) 918 (74) 583 (77) 95 (20) 1770 (43) 
> 80 0 (0) 0 (0) 7 (2) 20 (2) 71 (9) 362 (75) 460 (11) 
Female 0 (0) 673 (96) 190 (59) 1248 (100) 0 (0) 373 (78) 2484 (60) 
Body mass index, kg/m
2
 
     
 < 18.5 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 18 (4) 22 (1) 
18.5-25 
65 (11) 
79 (11) 10 (3) 178 (14) 157 (21) 185 (38) 674 (16) 
25-30 272 (45) 318 (45) 70 (22) 492 (39) 422 (56) 160 (33) 1734 (42) 
> 30 260 (43) 304 (43) 241 (75) 576 (46) 178 (23) 116 (24) 1675 (41) 
Atrial fibrillation 106 (18) 35 (5) 106 (33) 397 (32) 334 (44) 246 (51) 1224 (30) 
Coronary artery disease 340 (57) 365 (52) 213 (66) 533 (43) 468 (62) 216 (45) 2135 (52) 
Diabetes mellitus 161 (27) 164 (23) 321 (100) 281 (23) 132 (17) 73 (15) 1132 (28) 
Hyperlipidemia 284 (47) 296 (42) 271 (84) 533 (43) 280 (37) 138 (29) 1802 (44) 
Valvular disease 15 (2) 10 (1) 66 (20. 124 (10) 92 (12) 135 (28) 442 (11) 
Alcohol use 122 (20) 15 (2) 44 (14) 65 (5) 151 (20) 48 (10) 445 (11) 
Est. GFR, ml/min/1.73 m
2
 
     
 > 90 187 (31) 332 (47) 40 (12) 14 (1) 13 (2) 5 (1) 591 (14) 
60-90 342 (57) 340 (49) 71 (22) 765 (61) 441 (58) 90 (19) 2049 (50) 
30-60 63 (10) 21 (3) 170 (53) 445 (36) 296 (39) 320 (67) 1315 (32) 
< 30 2 (0) 0 (0) 33 (10) 0 (0) 0 (0) 61 (13) 96 (2) 
Hematocrit, % 
 
     
 > 50 61 (10) 3 (0) 5 (2) 33 (3) 44 (6) 7 (1) 153 (4) 
40-50 522 (87) 388 (55) 78 (24) 823 (66) 545 (72) 173 (36) 2529 (61) 
30-40 0 (0) 296 (42) 226 (70) 356 (29) 149 (20) 279 (58) 1306 (32) 
<30 0 (0) 0 (0) 2 (1) 1 (0) 1 (0) 7 (1) 11 (0) 
Other variables, median [IQR] 
      
LV ejection fraction, % 56 [51-62] 60 [55-67] 60 [54-65] 60 [54-66] 55 [50-63] 59 [52-65] 59 [52-65] 
SBP, mm Hg 
140  
[130-145] 
140  
[130-145] 
136  
[125-147] 
140  
[130-147] 
135  
[125-145] 
136  
[125-147] 
138  
[128-145] 
NT-proBNP, pg/ml 
215  
[85-572] 
143  
[73-310] 
448  
[181-1149] 
321  
[144-908] 
556  
[237-1238] 
950  
[361-1916] 
339  
[134-964] 
Est. GFR = Estimated glomerular filtration rate; SBP = systolic blood pressure 
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Table 1a – Distributions of latent class analysis variables according to HFpEF 
subgroup, CHARM-Preserved 
*Lower in all CHARM-Preserved patients vs. all I-PRESERVE patients, p<0.001 
†Higher in all CHARM-Preserved patients vs. all I-PRESERVE patients, p<0.001 
  
 Subgroup 
 
A B C D E F  All 
Latent class variable 677 (22) 259 (9) 288 (10) 604 (20) 862 (29) 333 (11) 3023 
Age, years* 
     
 
 < 60 228 (34) 48 (19) 81 (28) 170 (28) 303 (35) 25 (8) 855 (28) 
60-70 449 (66) 211 (81) 109 (38) 82 (13) 65 (8) 13 (4) 929 (31) 
70-80 0 (0) 0 (0.0) 95 (33) 349 (58) 467 (54) 64 (19) 975 (32) 
>80 0 (0) 0 (0.0) 3 (1) 3 (0) 27 (3) 231 (69) 264 (9) 
Female* 0 (0) 244 (94) 127 (44) 604 (100) 0 (0) 237 (71) 1212 (40) 
BMI*, kg/m
2
 
     
  
< 18.5 2 (0) 0 (0) 0 (0) 0 (0) 0 (0) 21 (6) 23 (1) 
18.5-25 100 (15) 51 (20) 12 (4) 122 (20) 233 (27) 163 (49) 681 (23) 
25-30 258 (38) 74 (29) 59 (21) 228 (38) 465 (54) 94 (23) 1178 (39) 
> 30 315 (47) 133 (51) 217 (75) 252 (42) 158 (18) 53 (16) 1128 (37) 
NA 2 (0) 1 (0) 0 (0) 2 (0) 6 (1) 2 (1) 13 (0) 
Atrial fibrillation* 57 (8) 1 (0) 31 (11) 121 (20) 163 (19) 105 (32) 478 (16) 
Coronary artery disease† 495 (73) 171 (66) 244 (85) 352 (58) 661 (77) 180 (54) 2103 (66) 
Diabetes mellitus 188 (28) 71 (27) 287 (100) 136 (23) 129 (15) 46 (14) 857 (28) 
Hyperlipidemia 330 (49) 113 (44) 229 (80) 186 (31) 352 (41) 52 (16) 1262 (39) 
Valvular disease* 38 (6) 14 (5) 88 (31) 141 (23) 180 (21) 146 (44) 607 (20) 
Alcohol use* 47 (7) 0 (0) 13 (5) 2 (0) 42 (5) 9 (3) 113 (4) 
Est. GFR*, ml/min/1.73 m
2
 
     
  
> 90 103 (15) 80 (31) 18 (6) 6 (1) 4 (0) 1 (0) 212 (7) 
60-90 77 (11) 25 (10) 40 (14) 130 (22) 133 (15) 16 (5) 381 (13) 
30-60 12 (2) 6 (2) 100 (35) 62 (10) 94 (11) 78 (23) 352 (12) 
15-30 0 (0.0) 0 (0) 23 (8) 0 (0) 0 (0) 29 (9) 52 (2) 
NA 485 (77) 148 (57) 107 (37) 406 (67) 631 (73) 209 (63) 1986 (66) 
Hematocrit*, % 
     
  
> 50 14 (2) 0 (0) 0 (0) 1 (0) 10 (1) 0 (0) 25 (1) 
40-50 183 (27) 49 (19) 38 (13) 89 (15) 154 (18) 33 (10) 546 (18) 
30-40 0 (0) 65 (25) 145 (50) 104 (17) 81 (9) 81 (24) 476 (16) 
< 30 0 (0) 0 (0) 9 (3) 0 (0) 0 (0) 12 (4) 21 (1) 
NA 480 (71) 145 (56) 96 (33) 410 (68) 617 (72) 207 (62) 1955 (65) 
Other variables, median [IQR] 
     
  
LV ejection fraction, % 
50  
[45-59] 
56 
[50-63] 
54 
[47-60] 
55 
[48-60] 
50  
[45-58] 
56  
50-63] 
52 
[46-60] 
SBP, mm Hg 
134 
[120-149] 
138 
[126-150] 
138 
[122-140] 
140 
[125-150] 
134 
[120-148] 
137 
[122-150] 
136 
[120-150] 
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Table 2a – Probability of primary and secondary outcomes at 3 years according to 
subgroup in I-PRESERVE, irbesartan vs. placebo, % (95% CI) 
 
Placebo  
 
Irbesartan  
Subgroup Total Primary, % Secondary, %   Total All events, % HF events, % 
A 310 20 (16-25) 7 (4-10) 
 
291 20 (16-25) 9 (6-13) 
B 348 13 (10-17) 5 (3-8) 
 
353 12 (9-16) 5 (4-8) 
C* 163 44 (37-52) 26 (20-34) 
 
159 32 (25-39) 13 (10-16) 
D 626 22 (19-25) 13 (10-16) 
 
622 24 (21-28) 23 (17-30) 
E 350 40 (35-45) 20 (16-24) 
 
410 35 (31-40) 15 (12-19) 
F 257 49 (43-56) 30 (24-36)   224 41 (35-48) 26 (21-33) 
*Irbesartan interaction hazard ratio 0.72 (0.53-0.99), p=0.046
 
 
Table 2b – Probability of primary outcome and secondary outcomes at 3 years 
according to subgroup in CHARM-Preserved, candesartan vs. placebo, % (95% CI) 
 
 
Placebo 
 
Candesartan 
Subgroup Total Primary, % Secondary, %   Total Primary, % Secondary, % 
A 329 32 (27-37) 12 (9-16) 
 
348 31 (26-36) 11 (8-14) 
B 125 33 (26-42) 10 (6-17) 
 
134 28 (21-36) 10 (6-16) 
C 144 56 (48-64) 36 (28-44) 
 
144 55 (47-64) 29 (22-38) 
D 317 39 (34-45) 19 (15-24) 
 
287 33 (28-39) 13 (10-18) 
E 415 41 (36-46) 17 (14-21) 
 
444 38 (34-43) 15 (12-19) 
F 175 54 (47-62) 35 (28-43)   157 53 (46-62) 28 (22-37) 
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Table 3a – Hazard ratios associated with subgroup + full multivariate model and 
primary outcome, I-PRESERVE, continuous variables 
 
*Hazard ratios correspond to probability of membership in given 
subgroup=1 compared to 0.  Subgroup F is not listed because 
sum of probabilities for all subgroups=1. 
†Likelihood ratio test p<0.001, K statistic increased from 0.66 to 
0.67 when subgroup added to full multivariate model. 
  
Predictor Hazard Ratio (95% CI) p-value 
Age, year 1.04 (1.03-1.05) <0.001 
Female 0.71 (0.64-0.80) <0.001 
Atrial fibrillation 1.55 (1.38-1.74) < 0.001 
Coronary artery disease 1.30 (1.17-1.46) < 0.001 
Diabetes mellitus 1.64 (1.44-1.90) < 0.001 
Hyperlipidemia 0.78 (0.69-0.87) < 0.001 
Valvular disease 1.20 (1.03-1.39) 0.016 
Alcohol use 0.83 (0.70-0.99) 0.036 
Body mass index, kg/m
2
 1.01 (1.00-1.02) 0.055 
eGFR, ml/min/1.73 m
2
 0.992 (0.989-0.995) <0.001 
Hematocrit, % 0.99 (0.98-1.00) 0.12 
SBP, mm Hg 1.000 (0.996-1.003) 0.93 
LV ejection fraction 0.98 (0.98-0.99) <0.001 
NT-proBNP, 100 pg/mL 1.008 (1.007-1.010) <0.001 
Subgroup
*,†
 
  A 0.64 (0.40-1.02) 0.063 
B 0.31 (0.20-0.50) <0.001 
C 0.83 (0.54-1.27)) 0.39 
D 0.55 (0.41-0.75) <0.001 
E 0.80 (0.57-1.13) 0.20 
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Table 3b – Hazard ratios associated with subgroup + full multivariate model and 
primary outcome, CHARM-Preserved, continuous variables, all ages 
 
*Hazard ratios correspond to probability of membership in given 
subgroup=1 compared to 0.  Subgroup F is not listed because 
sum of probabilities for all subgroups=1. 
†Likelihood ratio test p=0.31, K statistic increased from 0.629 to 
0.630 when subgroup added to full multivariate model 
  
Predictor Hazard Ratio (95% CI) p-value 
Age, year 1.02 (1.01-1.03) <0.001 
Female 0.92 (0.69-1.22) 0.54 
Atrial fibrillation 1.28 (1.09-1.50) 0.003 
Coronary artery disease 1.11 (0.97-1.28) 0.14 
Diabetes mellitus 1.42 (1.19-1.70) <0.001 
Hyperlipidemia 0.82 (0.71-0.93) 0.003 
Valvular disease 1.15 (1.00-1.34) 0.054 
Alcohol use 0.89 (0.64-1.24) 0.51 
Body mass index, kg/m
2
 1.00 (0.99-1.01) 0.91 
eGFR, ml/min/1.73 m
2
 0.993 (0.988-0.998) 0.012 
Hematocrit, % 0.97 (0.95-1.00) 0.039 
SBP, mm Hg 0.997 (0.994-1.000) 0.093 
LV ejection fraction 1.14 (0.61-2.14) 0.67 
Subgroup
*,†
 
  A 0.95 (0.59-1.53) 0.84 
B 0.83 (0.52-1.30) 0.41 
C 1.38 (0.84-2.28) 0.21 
D 0.81 (0.55-1.17) 0.26 
E 0.96 (0.64-1.44) 0.85 
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Table 3c – Hazard ratios associated with subgroup + full multivariate model and 
primary outcome, CHARM-Preserved, continuous variables, age ≥60 
 
*Hazard ratios correspond to probability of membership in given 
subgroup=1 compared to 0.  Subgroup F is not listed because 
sum of probabilities for all subgroups=1. 
†Likelihood ratio test p=0.27, K statistic increased from 0.620 to 
0.622 when subgroup added to full multivariate model 
 
 
 
 
Predictor Hazard Ratio (95% CI) p-value 
Age, year 1.03 (1.02-1.05) <0.001 
Female 0.96 (0.71-1.31) 0.80 
Atrial fibrillation 1.32 (1.11-1.57) 0.001 
Coronary artery disease 1.08 (0.93-1.26) 0.30 
Diabetes mellitus 1.47 (1.21-1.78) <0.001 
Hyperlipidemia 1.12 (0.96-1.31) 0.001 
Valvular disease 1.00 (0.98-1.01) 0.14 
Alcohol use 0.81 (0.53-1.23) 0.33 
Body mass index, kg/m
2
 1.00 (0.98-1.01) 0.66 
eGFR, ml/min/1.73 m
2
 0.995 (0.989-1.000) 0.04 
Hematocrit, % 0.97 (0.94-0.99) 0.006 
SBP, mm Hg 0.998 (0.994-1.001) 0.22 
LV ejection fraction 1.31 (0.66-2.60) 0.45 
Subgroup
*,†
 
  A 1.41 (0.77-2.60) 0.27 
B 1.12 (0.61-2.06) 0.71 
C 1.91 (1.06-3.46) 0.03 
D 0.97 (0.64-1.48) 0.91 
E 1.26 (0.79-1.99) 0.33 
